The projects of this HN SPORE will use human head and neck cancer specimens and cell lines fortranslational research directed toward improving the early detection, prevention, and treatment of head andneck cancer. The Tissue Procurement, Pathology and Biomarkers Core (Core C) provides investigators atM. D. Anderson Cancer Center and other collaborating institutions with high-quality tissue samples frompatients with head and neck cancer and oral premalignancies. The Head and Neck Tissue Bank, directed byCore Director, Dr. Adel EI-Naggar, now contains more than 338,000 specimens from more than 29,000patients. Standardized and centralized procedures have been established for tissue procurement, qualitycontrol, and processing, storage, and distribution of samples to individual investigators. In addition, Core Cprovides centralized, specialized services such as tissue microarray (TMA) construction, tissuemicrodissection, qualitative and quantitative biomarker analyses both in tissue [e.g., immunohistochemistry(IHC), Western blotting) and non-tissue (e.g., blood-based cytokine profiles) specimens, nucleic acidextractions, development and maintenance of cell lines. These services and expertise provided by Core Cwere a critical component of the past SPORE research activities, leading to over 158 publications during thepast five years, with 78 of these publications co-authored by Dr. EI-Naggar. This Core has been at theforefront of multi-institutional efforts to standardize pathologic terminology and criteria for reporting andevaluating pathologic specimens and analyses, and developing and integrating common data elements ofour Tissue Bank database with the NCI's CaBIG Initiative. This revised application provides significantlyenhanced detail regarding usage of the Core and how this resource has benefited the SPORE projects, itseffectiveness and value, and its extensive contributions to InterSPORE and other NIH/NCI initiatives.Specifically, we have added lists of specimen acquisition and core users, details regarding our qualitycontrol procedures, and various methodologies related to our specialized services.
Specific Aims of theCore include: 1) To obtain, process, and maintain a repository of premalignant, tumorous, and matchingnon-tumorous specimens, and related specimens, and to distribute and track utilization of specimens; 2) Tomaintain and expand innovative and unique tissue and blood-based resources and histopathologic services;3) To perform and interpret various tissue- and blood-based methodologies with rigorous quality control,maximize tissue utilization, and ensure the successful completion of each project's aims; and 4) To fosterand support inter-SPORE and other NCI/NIH interactions and collaborations. The Core will continue toensure the highest quality tissue samples and related analyses will be provided to all HN SPOREinvestigators, as well as to collaborating researchers participating in other NIH/NCI-sponsored programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097007-06A1
Application #
7510674
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2008-08-01
Project End
2013-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
6
Fiscal Year
2008
Total Cost
$223,377
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Multidisciplinary Larynx Cancer Working Group; Mulcahy, Collin F; Mohamed, Abdallah S R et al. (2018) Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. Head Neck 40:2060-2069
Kamal, Mona; Mohamed, Abdallah S R; Volpe, Stefania et al. (2018) Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry. Radiother Oncol 128:442-451
López Alfonso, Juan Carlos; Parsai, Shireen; Joshi, Nikhil et al. (2018) Temporally feathered intensity-modulated radiation therapy: A planning technique to reduce normal tissue toxicity. Med Phys 45:3466-3474
Pai, Sara I; Jack Lee, J; Carey, Thomas E et al. (2018) HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncol 77:92-97
Lu, Zhongming; Sturgis, Erich M; Zhu, Lijun et al. (2018) Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx. Mol Carcinog 57:361-369
Elhalawani, Hesham; Lin, Timothy A; Volpe, Stefania et al. (2018) Machine Learning Applications in Head and Neck Radiation Oncology: Lessons From Open-Source Radiomics Challenges. Front Oncol 8:294
Yin, Guosheng; Chen, Nan; Lee, J Jack (2018) Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint. Stat Biosci 10:420-438
Antczak, Nicole M; Walker, Alice R; Stern, Hannah R et al. (2018) Characterization of Nine Cancer-Associated Variants in Human DNA Polymerase ?. Chem Res Toxicol 31:697-711
MD Anderson Head and Neck Cancer Symptom Working Group; Kamal, Mona; Rosenthal, David I et al. (2018) Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. Radiother Oncol 126:75-80
Joint Head and Neck Radiotherapy-MRI Development Cooperative (2018) Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers. Sci Data 5:180008

Showing the most recent 10 out of 370 publications